Prime Therapeutics Announces Oncology Management Program
New offering promotes evidence-based treatments and quality patient care
ST. PAUL, Minn., Feb. 23, 2012 /PRNewswire/ -- Prime Therapeutics (Prime), a leading pharmacy benefit manager (PBM), has announced its new oncology management program designed to improve the quality and value of cancer care for patients. Prime plans to partner with two oncology management companies in bringing this new capability to its health plan clients.
Prime has entered into an agreement with eviti, Inc., a leading health information technology company delivering web-based decision support services. Through an oncology clinical decision-support platform, eviti improves the quality of cancer care and reduces costs by aiding in the selection of the most appropriate treatment plan for each patient based on diagnosis and other clinical and personal considerations. With eviti, Prime's health plan clients' network physicians will have real-time access to a digital clinical library of more than 1,000 evidence-based treatment options for at least 120 cancer types. All treatment options display regimen details and toxicity, and comparison of outcomes and costs.
"Our health plan clients face a wide spectrum of oncology management challenges uniquely driven by the markets they serve. Most critical is to ensure appropriate treatment for patients dealing with these protocols, and we believe eviti's extensive clinical oncology expertise will allow us to effectively manage this area," said Eric Elliott, president and CEO of Prime.
By utilizing actionable information accessible at the moment of clinical prescribing, eviti ensures quality care is prescribed from the start. Treatments selected through eviti's automated process can streamline workflow, reducing the administrative burden sometimes associated with prior authorization calls, appeals and denials. In addition, eviti alerts appropriate care team members for early enrollment of patients in case management, and optimal fulfillment of prescription medications.
"Prime's selection of eviti affirms the importance of an independent, comprehensive oncology decision support platform to effectively manage the high cost of cancer care and ensure appropriate treatment for patients. Together with Prime 's innovative oncology management solutions, we plan to improve the quality of cancer care," said Eduardo Beruff, president and CEO of eviti, Inc.
Prime Therapeutics is a pharmacy benefit management company dedicated to providing innovative, clinically-based, cost-effective pharmacy solutions for clients and members. Providing pharmacy benefit services nationwide to nearly 20 million* lives, its client base includes Blue Cross and Blue Shield Plans, employer and union groups, and third-party administrators. Headquartered in St. Paul, Minn., Prime Therapeutics is collectively owned by 13 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those Plans. Learn more at www.primetherapeutics.com.
eviti, Inc. (formerly known as ITA Partners, Inc.) is a leading health information technology company delivering web-based decision-support services to improve the quality of cancer care and reduce its cost. eviti represents the culmination of almost a decade of experience providing oncology treatment intelligence, uniquely delivering value to all parties in the care process by ensuring quality care is prescribed from the start. eviti's independent, non-proprietary digital oncology treatment library is one of the most comprehensive and current of its kind, meticulously compiled from the world's leading sources. For more information, visit www.eviti.com.
SOURCE Prime Therapeutics